High-Risk HPV Evaluated for Invasive Cervical Cancer
By LabMedica International staff writers Posted on 29 Oct 2018 |
Image: The MAGPIX compact multiplexing unit performs up to 50 different tests in a single reaction volume and reads a 96-well-plate in just 60 minutes (Photo courtesy of Luminex).
Cervical cancer is a major cause of morbidity and mortality in women worldwide and the role of high-risk human papillomavirus (hrHPV) in the development of invasive cervical cancer (ICC) is well established.
Persistent infection with hrHPV in the cervical epithelium, especially types HPV16 and HPV18, is known to be associated with higher probability of progression to cervical intraepithelial lesion grade 3 (CIN3) and ICC compared to being negative for such infection.
Scientists at the Karolinska Institutet (Stockholm, Sweden) and their colleagues identified all ICC diagnosed in Sweden during the years 2002–2011 (4,254 confirmed cases), requested all archival formalin-fixed paraffin-embedded blocks (FFPE), and performed HPV genotyping. Twenty out of 25 pathology biobanks agreed to the study, yielding a total of 2,845 confirmed cases with valid HPV results. Cases were prospectively followed up from date of cancer diagnosis to December 31, 2015. All FFPE blocks were extracted and tested in parallel with β-globin real-time polymerase chain reaction (PCR) and HPV genotyping using general primers (MGP)-PCR targeting the L1 region, followed by typing with Luminex for 13 high-risk types.
The investigators reported that of the 2,845 included cases, hrHPV was detected in 2,293 (80.6%), and they observed 1,131 (39.8%) deaths during an average of 6.2 years follow-up. The majority of ICC cases were diagnosed at age 30–59 years (57.5%) and classified as stage IB (40.7%). hrHPV positivity was significantly associated with screen-detected tumors, young age, high education level, and early stage at diagnosis. The 5-year relative survival ratios (RSR) compared to the general female population was 0.74 for hrHPV-positive cases and 0.54 for hrHPV-negative cases, yielding a crude excess hazard ratio (HER) of 0.45 and an adjusted EHR of 0.61.
The authors concluded that women with hrHPV-positive cervical tumors had a substantially better prognosis than women with hrHPV-negative tumors. hrHPV appears to be a biomarker for better prognosis in cervical cancer independent of age, International Federation of Gynecology and Obstetrics (FIGO) stage, and histological type, extending information from already established prognostic factors. The study was published on October 1, 2018, in the PLOS Medicine.
Related Links:
Karolinska Institutet
Persistent infection with hrHPV in the cervical epithelium, especially types HPV16 and HPV18, is known to be associated with higher probability of progression to cervical intraepithelial lesion grade 3 (CIN3) and ICC compared to being negative for such infection.
Scientists at the Karolinska Institutet (Stockholm, Sweden) and their colleagues identified all ICC diagnosed in Sweden during the years 2002–2011 (4,254 confirmed cases), requested all archival formalin-fixed paraffin-embedded blocks (FFPE), and performed HPV genotyping. Twenty out of 25 pathology biobanks agreed to the study, yielding a total of 2,845 confirmed cases with valid HPV results. Cases were prospectively followed up from date of cancer diagnosis to December 31, 2015. All FFPE blocks were extracted and tested in parallel with β-globin real-time polymerase chain reaction (PCR) and HPV genotyping using general primers (MGP)-PCR targeting the L1 region, followed by typing with Luminex for 13 high-risk types.
The investigators reported that of the 2,845 included cases, hrHPV was detected in 2,293 (80.6%), and they observed 1,131 (39.8%) deaths during an average of 6.2 years follow-up. The majority of ICC cases were diagnosed at age 30–59 years (57.5%) and classified as stage IB (40.7%). hrHPV positivity was significantly associated with screen-detected tumors, young age, high education level, and early stage at diagnosis. The 5-year relative survival ratios (RSR) compared to the general female population was 0.74 for hrHPV-positive cases and 0.54 for hrHPV-negative cases, yielding a crude excess hazard ratio (HER) of 0.45 and an adjusted EHR of 0.61.
The authors concluded that women with hrHPV-positive cervical tumors had a substantially better prognosis than women with hrHPV-negative tumors. hrHPV appears to be a biomarker for better prognosis in cervical cancer independent of age, International Federation of Gynecology and Obstetrics (FIGO) stage, and histological type, extending information from already established prognostic factors. The study was published on October 1, 2018, in the PLOS Medicine.
Related Links:
Karolinska Institutet
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities